<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(12)</volume><submitter>You W</submitter><pubmed_abstract>Interleukin enhancer binding factor 2 (ILF2) has been confirmed to drive the progression and proliferation of multiple malignancies, but the expression and function of ILF2 in colorectal cancer (CRC) remain to be elucidated. In this study, the expression of ILF2 in CRC tissues was evaluated by the public tumor databases, quantitative reverse transcription PCR (qRT-PCR) and tissue array analyses. ILF2 was found to be elevated in CRC, and was predicted to serve as a negative index for patients. Subsequently, cell proliferation was detected by Cell Counting Kit-8 (CCK-8) assay and colony formation, and tumor growth was evaluated by establishing xenografted mouse models. Our results showed that knockout of ILF2 markedly inhibited cell proliferation and tumor growth of CRC. Moreover, we found I</pubmed_abstract><journal>American journal of cancer research</journal><pagination>5281-5292</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12789919</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>USP5-mediated stabilization of ILF2 via deubiquitination drives the tumor growth of colorectal cancer.</pubmed_title><pmcid>PMC12789919</pmcid><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Han K</pubmed_authors><pubmed_authors>Chen G</pubmed_authors><pubmed_authors>Yang P</pubmed_authors><pubmed_authors>Cui X</pubmed_authors><pubmed_authors>You W</pubmed_authors><pubmed_authors>Xu X</pubmed_authors><pubmed_authors>Ye J</pubmed_authors></additional><is_claimable>false</is_claimable><name>USP5-mediated stabilization of ILF2 via deubiquitination drives the tumor growth of colorectal cancer.</name><description>Interleukin enhancer binding factor 2 (ILF2) has been confirmed to drive the progression and proliferation of multiple malignancies, but the expression and function of ILF2 in colorectal cancer (CRC) remain to be elucidated. In this study, the expression of ILF2 in CRC tissues was evaluated by the public tumor databases, quantitative reverse transcription PCR (qRT-PCR) and tissue array analyses. ILF2 was found to be elevated in CRC, and was predicted to serve as a negative index for patients. Subsequently, cell proliferation was detected by Cell Counting Kit-8 (CCK-8) assay and colony formation, and tumor growth was evaluated by establishing xenografted mouse models. Our results showed that knockout of ILF2 markedly inhibited cell proliferation and tumor growth of CRC. Moreover, we found I</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-06-06T13:14:30.706Z</modification><creation>2026-05-30T03:11:31.141Z</creation></dates><accession>S-EPMC12789919</accession><cross_references><pubmed>41523258</pubmed><doi>10.62347/FSPT8923</doi><doi>10.62347/fspt8923</doi></cross_references></HashMap>